Apricus Biosciences, Inc. (APRI)

Oncology Corporate Profile

Stock Performance

0.5400
0.0000

HQ Location

6330 Nancy Ridge Drive, Suite 103
San Diego, CA 92121

Company Description

Apricus Bio is a San Diego-based specialty pharmaceutical company, with commercial products and a broad pipeline across numerous therapeutic classes. Revenues and growth are driven from the sales of the Company's commercial products through its Apricus Pharmaceuticals USA, Inc. and NexMed (USA), Inc. subsidiaries and through out-licensing in certain territories of its product pipeline and NexACT¥Ô technology. Apricus Bio currently markets Totect¥Ô (dexrazoxane HCl), the only drug approved in the US for the treatment of anthracycline extravasation. Apricus Bio's current pipeline includes Vitaros¥Ô, approved in Canada for the treatment of erectile dysfunction, as well as compounds in development from pre-clinical through pre-registration currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Consumer Healthcare.

Website: http://www.apricusbio.com/

Brand Generic Indication
Granisol__¢granisetronGranisetron is indicated for the prevention of:



- Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin.

- Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.
Totect«•dexrazoxane HClTotect«• is indicated for the treatment of extravasation resulting from intravenous

anthracycline chemotherapy.

View additional information on commercial products here »

This company does not have any pipeline products

Source


http://www.apricusbio.com/

Recent News Headlines

Apricus reports 4Q loss

3/13/2017 09:02 pm

Apricus reports 4Q loss

3/13/2017 09:02 pm

Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results

3/13/2017 08:02 pm

[GlobeNewswire] - Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals Strengthens Financial Position Vitaros U.S. NDA Re-Submission on Track for Third Quarter 2017 Conference Call / Webcast Today, Monday, ...

Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results

3/13/2017 08:01 pm

[GlobeNewswire] - Vitaros Assets and Rights to Ferring Pharmaceuticals Strengthens Financial Position. NDA Re-Submission on Track for Third Quarter 2017. Conference Call/ Webcast Today, Monday, March 13, 2017 at 4:30 p.m. ...

Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call

3/9/2017 12:00 pm

[GlobeNewswire] - SAN DIEGO, March 09, 2017-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and full ...

Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call

3/9/2017 12:00 pm

[GlobeNewswire] - Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company`s fourth quarter and full year 2016 financial ...

Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals

3/8/2017 09:00 pm

[GlobeNewswire] - Apricus Expects to Receive Approximately $12.7 Million from Ferring. Apricus to Focus on Vitaros U.S. NDA Re-Submission and Pipeline Assets Post-Closing.

Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals

3/8/2017 09:00 pm

[GlobeNewswire] - Apricus Expects to Receive Approximately $12.7 Million from Ferring Apricus to Focus on Vitaros U.S. NDA Re-Submission and Pipeline Assets Post-Closing SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- Apricus ...

Apricus Biosciences Receives Positive Nasdaq Listing Determination

2/9/2017 11:00 am

[GlobeNewswire] - SAN DIEGO, Feb. 09, 2017-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that on February 8, 2017, the Company was notified ...

Apricus Biosciences Receives Positive Nasdaq Listing Determination

2/9/2017 11:00 am

[GlobeNewswire] - SAN DIEGO, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that on February ...

Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference

2/8/2017 12:00 pm

[GlobeNewswire] - SAN DIEGO, Feb. 08, 2017-- Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, ...

Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference

2/8/2017 12:00 pm

[GlobeNewswire] - SAN DIEGO, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard ...